Assessing the Equity of Reach: Virtual Medical Visits Among Asthma Patients During the COVID-19 Pandemic

Join us as this presenter discusses this poster live on May 25, 2021 | Track A at 1:00 PM Mountain

PRESENTER
JO ANN SHOUP, PhD
Kaiser Permanente Colorado
BACKGROUND
The COVID-19 pandemic has affected routine asthma care, requiring rapid adaptation from in-person to virtual healthcare. Deleterious outcomes (e.g. hospitalization, death) may have been associated with not receiving early treatment for asthma exacerbations. Additionally, existing health disparities may have created an even wider chasm of care for under-represented racial and minority groups. Telehealth may help to bridge this gap, but the extent of the transition to virtual care among asthma patients, and across race and ethnicity, is unknown. We used the RE-AIM framework to examine the equitable reach and representativeness of virtual asthma visits among patients in an integrated healthcare system during the pandemic.
SETTING/POPULATION
Patients diagnosed with persistent asthma within a single-site integrated healthcare setting which had existing infrastructure for virtual care (email, telephone, video visit, or chat-with-the-doc) prior to the pandemic.
METHODS
Using International Classification Diagnostic (ICD-10) codes, we identified members with persistent asthma. Covariates included self-reported race, ethnicity, age, sex, and healthcare utilization prior to COVID-19. We determined income and education using census tract geo-coding. We categorized ethnicity as Latinx, and race as Asian, Black/African American, White, Other (Alaskan Native/American Indian or Native Hawaiian/Other Pacific Islander) and Unknown. To assess the association between race or ethnicity and use of virtual visits for asthma care, we used logistic regression and adjusted the model using covariates. We defined the dependent variable, visit type, as in-person only versus virtual visits for those who had one or more visits within the health system or any hospital.
RESULTS
Of 5796 asthma patients, 60.6% used virtual care March through October 2020. Race or ethnicity were not significantly associated with higher or lower use of virtual care visits during the pandemic: Latinx versus White (adjusted odds ratio [aOR]=1.02,95% confidence interval [CI]=0.87-1.18); Asian versus White (aOR=0.98,95% CI=0.66-1.45); Black versus White (aOR=1.16,95% CI=0.92-1.46); Other versus White (aOR=0.89,95% CI=0.69-1.15); Unknown versus White (aOR=0.85,95%CI=0.61-1.18).
CONCLUSIONS
RE-AIM’s dimension of reach guided measures of equitable healthcare access during a time of rapid adaptation of asthma care delivery due to the pandemic. Within an integrated health care system with existing virtual visit options and whose members had health insurance, use of virtual asthma care visits did not differ by race or ethnicity. It remains imperative to assess virtual healthcare access and use across multiple health conditions, across organizations without existing capacity for virtual medical care and in those with access barriers.
POSTER

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Development of the Direct Oral Anticoagulants Dashboard for Pharmacists to Optimize Care for Veterans

Join us as this presenter discusses this poster live on May 25, 2021 | Track A at 1:00 PM Mountain

PRESENTER
ANJU SAHAY, PhD
Veterans Affairs Palo Alto Health Care System
BACKGROUND
The focus of the Department of Veteran Affairs’ (VA) Medication Safety (MedSafe) QUERI Program is to reduce potentially unsafe or unnecessary medications for Veterans. We conducted the national evaluation on the utilization of the VA Office of Pharmacy Benefits Management (PBM) Service’s Center for Medication Safety (VAMedSAFE) Web application called the Medication Use Evaluation Tracker (MUET). On a monthly/quarterly basis this application identifies at-risk Veterans across all VA sites.
 
Our national evaluation confirmed interest in PBM/VAMedSAFE development of national medication safety and appropriate use of dashboards to identify and reduce potentially unsafe medication utilization. The Direct Oral Anticoagulant (DOAC) patient management tool was developed as a facility/VISN initiative and was evaluated as a candidate for national use based on the occurrence of adverse events and risk of therapeutic failures related to DOAC therapy. VAMedSAFE validated and optimized the report with the developer, and in conjunction with our MedSafe QUERI Program the DOAC Dashboard became the first national medication safety dashboard.
SETTING/POPULATION
Development of five national dashboards.
METHODS
In September 2017 in conjunction with PBM, the MedSafe QUERI Program invited subject matter experts, VISN (Regional) Pharmacy Executives and other key stakeholders to form the PBM VAMedSAFE National Medication Safety Dashboard Advisory Committee. The role of this Committee has been to coordinate and approve dashboard solutions that relate to VAMedSAFE national projects and initiatives. This Committee meets on a quarterly basis and has prioritized the development or adoption of five National Dashboards as mediation safety/appropriate use population health management tools. These dashboards are designed to identify at-risk Veterans across all the VA sites with regular data updates and daily accessibility to clinicians.
RESULTS
In July 2019, the DOAC Dashboard was made available at all 146 VA sites (18 VISNs) for the monitoring of all patients prescribed DOAC therapy. By December 2020, the DOAC Dashboard use has been documented at 122 (84%) sites where staff at these sites have utilized the DOAC Dashboard to complete at least one write-back (an administrative marker for the use of this Dashboard).
 
At these 122 (84%) sites, a total of 1,500 staff have previously and/or currently use the DOAC Dashboard. In contrast, as yet no write-back has been received from the remaining 24 (16%) sites. This Dashboard has already served a total of 173,918 Veterans.
 
The remaining four dashboards at various stages of development are: Proton Pump Inhibitors Dashboard, AntiCD20 Antibody Dashboard, Direct-Acting Antivirals-Hepatitis B Monitoring/Re-activation Dashboard andAzathioprine/6-Mercaptopurine Dashboard.
CONCLUSIONS
As a population health management tool, the DOAC Dashboard provides oversight for the monitoring of treatment for DOACs.
POSTER

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab